Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses challenges in obtaining finasteride in the Netherlands and explores alternatives like natural DHT blockers and topical finasteride. Suggestions include consulting different doctors or dermatologists and considering cost-effective options like cutting higher-dose tablets.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

The conversation is about someone who has been using finasteride and minoxidil for over three years without satisfactory results for hair thinning. They have started using dutasteride and added RU58841 seven months ago but have not seen improvements yet.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

A user shared a 14-month hair loss treatment update using dutasteride, minoxidil foam, a 1.5mm derma roller, and Nizoral, with noticeable hair regrowth and no side effects. The discussion highlights the effectiveness of microneedling in combination with topical treatments, with many users agreeing it significantly enhances results.

A user is considering using RU58841 to treat hair loss and asks if it can be effective for 4-5 years. Some suggest starting with a lower concentration and debate the safety of RU58841 compared to approved drugs like finasteride.

Rapamycin, finasteride, and minoxidil are discussed as a strategy for hair loss prevention and reversal. Pulsed dosing of rapamycin is suggested to avoid conflicting effects with minoxidil.

The user is considering switching from topical finasteride to RU58841 or KX826 due to side effects like low libido and ED. They are also using oral minoxidil and considering low-dose saw palmetto to maintain their hairline.

A user shared their 3-month hair growth progress using 1mg oral finasteride, 5% topical minoxidil, and microneedling with a 1.5 mm dermaroller twice weekly. The user received positive feedback and expressed a desire for thicker hair in the future.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

A 28-year-old has been using oral dutasteride 0.5 mg, topical minoxidil 5%, and Cafune shampoo for 104 days with positive results and is considering adding microneedling. No side effects from dutasteride have been reported.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The user has been microneedling at 0.25mm once a week for 4 weeks and noticed further hairline recession. They are concerned about the impact of vitamin deficiencies, like biotin, on hair growth.

A user shared an extensive hair loss treatment regimen including dutasteride, minoxidil, tadalafil, RU58841, microneedling, and various topical and oral supplements. Responses varied, with some suggesting the regimen is excessive and others offering additional advice or expressing skepticism about its practicality and effectiveness.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Microneedling is discussed as a favorable hair loss treatment, with no consensus on whether to glide or remove the device between areas. Scalp irritation varies by individual, and some users report no need for gel during the process.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

The user is seeking advice on sourcing finasteride, dutasteride, and minoxidil, as their doctors are unwilling to prescribe both finasteride/dutasteride and minoxidil simultaneously. They are also looking for sources of GHK-Cu and RU58841 in the USA, with suggestions including using services like Hims, ro.co, and Musely.

Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.

A 32-year-old is seeing positive hair regrowth after nearly three months using finasteride, oral and liquid minoxidil, and microneedling, and plans to add RU58841. They are considering switching to dutasteride and possibly a hair transplant in the future.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

Ninan50 uses 0.6 minoxidil, 0.05 finasteride, biotin, and dermarolling for hair loss. Plans to increase to 0.7 minoxidil and 0.125 finasteride, with positive progress seen.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

A female user is using a 5% RU58841 solution with 5 sprays daily and is concerned about potential reactions and the impact of wearing a bonnet. A male user mentioned using 1ml of the same solution daily via dropper.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

The post and conversation are about a user's progress with microneedling and minoxidil for hair loss. The user is happy with the progress and plans to continue with the treatment, without using finasteride.

The conversation discusses concerns about using hair fibers while microneedling, specifically the potential for clogging pores. It is suggested that microneedling should not cause bleeding.